查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602430

先进治疗 CDMO 市场：按产品、阶段、适应症和最终用户 - 2025-2030 年全球预测

Advanced Therapy Medicinal Products CDMO Market by Products (Cell Therapy, Gene Therapy, Tissue Engineered), Phase (Phase I, Phase II, Phase III), Indication, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

先进治疗CDMO市场2023年估值为75.4亿美元，预计到2024年将达到87.4亿美元，复合年增长率为17.06%，预计到2030年将达到227.4亿美元。

先进治疗药物 (ATMP)受託製造厂商(CDMO) 在生物技术和製药领域发挥着至关重要的作用，开发和开发基因疗法、细胞疗法和组织工程产品等创新治疗方法，我们为製造提供基本服务。随着对个人化医疗的需求不断增长以及其他无法治癒疾病的治疗方法的进步，对 ATMP 的需求更加突出，肿瘤学、罕见疾病、神经病学和再生医学的应用范围和最终用途正在扩大。该市场的关键成长要素包括细胞处理技术的进步、临床试验计划数量的增加以及加快产品核可流程的有利法规结构。然而，在增强可扩展的製造流程和自动化技术方面仍然存在潜在的机会。利用这些机会可能需要投资来促进与专注于奈米级解决方案和生产分析数位基础设施的生物技术公司的伙伴关係。然而，市场成长面临着高昂的製造成本、严格的监管要求和缺乏熟练劳动力的挑战，这可能会影响治疗药物的及时生产和供应。此外，供应链的复杂性和许多 ATMP 技术的早期阶段等限制因素也构成了进一步的障碍。创新和研究的最佳途径是改进反应器技术、改进基因编辑工具以及优化支援 ATMP 稳定性和分销的低温运输物流。强调与学术机构和生物技术创新者的合作也可以促进技术突破。市场是动态的，具有源于治疗方法进步和技术改进的高成长潜力，但必须克服监管和物流挑战，以保持竞争力并最大化市场占有率，您需要策略性地度过这一难关。

主要市场统计
基准年[2023] 75.4亿美元
预测年份 [2024] 87.4亿美元
预测年份 [2030] 227.4亿美元
复合年增长率（%） 17.06%

市场动态：快速发展的先进治疗 CDMO 市场的关键市场洞察

供需的动态交互作用正在改变先进疗法 CDMO 市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 新感染疾病的出现导致罕见疾病迅速增加
    • 增加尖端治疗药物开发的临床试验数量
    • 全球医药研发投入增加
  • 市场限制因素
    • 与外包 ATMP 解决方案相关的高成本
  • 市场机会
    • 尖端治疗 CDMO 采用尖端技术
    • 先进疗法研究和开发的策略联盟和扩展活动
  • 市场挑战
    • 关于 ATMP核准和商业化的严格政府规章制度

波特五力：引领进治疗 CDMO 市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解先进治疗 CDMO 市场的外部影响

外部宏观环境因素在塑造先进疗法 CDMO 市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解先进治疗药物 CDMO 市场的竞争状况

先进治疗 CDMO 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵先进疗法 CDMO 市场供应商绩效评估

FPNV定位矩阵是评估先进疗法CDMO市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划先进疗法 CDMO 市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，先进疗法 CDMO 市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 罕见疾病盛行率增加和新疾病出现

感染疾病

      • 增加先进治疗药物开发的临床试验
      • 全球药品研发投资增加
    • 抑制因素
      • 与外包 ATMP 解决方案相关的高成本
    • 机会
      • 采用先进技术和先进疗法

产品CDMO

      • 先进疗法研究和开发的策略联盟和扩展活动
    • 任务
      • ATMP核准和

商业化

  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章先进治疗药物 CDMO 市场：副产品

  • 细胞疗法
  • 基因治疗
  • 组织工程

第七章先进治疗药物 CDMO 市场分阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第八章先进治疗药物 CDMO 市场（按适应症）

  • 心臟病学
  • 中枢神经系统
  • 皮肤科
  • 内分泌、代谢、遗传学
  • 胃肠病学
  • 血液学
  • 免疫学和发炎
  • 感染疾病
  • 肌肉骨骼
  • 肿瘤学
  • 眼科

第九章先进治疗药物 CDMO 市场：依最终用户分类

  • 学术研究所
  • 生物技术和製药公司
  • 临床研究组织（CRO）
  • 医院和诊所

第10章：美洲先进治疗CDMO市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区先进治疗药物CDMO市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第12章：欧洲、中东和非洲先进治疗药物CDMO市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abzena
  • Advanced Therapies, Inc. by WuXi AppTec
  • AGC Inc.
  • Aldevron
  • Almac Group
  • Arranta Bio Holdings, LLC
  • Bio Elpida
  • BlueReg
  • Catalent Inc.
  • CELONIC Group
  • CGT Catapult
  • Charles River Laboratories International, Inc.
  • Coriolis Pharma Research GmbH
  • Eurofins Scientific SE
  • FUJIFILM Corporation
  • Lonza Group
  • Minaris Regenerative Medicine
  • Oxford Biomedica PLC
  • Patheon by Thermo Fisher Scientific Inc.
  • Rentschler Biopharma SE
  • REPROCELL Inc.
  • RoslinCT
  • Samsung Biologics
  • VIVEBIOTECH SL
Product Code: MRR-3A2E844FDCF6

The Advanced Therapy Medicinal Products CDMO Market was valued at USD 7.54 billion in 2023, expected to reach USD 8.74 billion in 2024, and is projected to grow at a CAGR of 17.06%, to USD 22.74 billion by 2030.

Advanced Therapy Medicinal Products (ATMPs) Contract Development and Manufacturing Organizations (CDMOs) play a pivotal role in the biotechnology and pharmaceutical sectors, offering essential services in the development and production of innovative therapies such as gene therapies, cell therapies, and tissue-engineered products. The necessity for ATMPs is underscored by the rising demand for personalized medicine and the advancement of treatments for otherwise incurable diseases, which has exponentially driven the application and end-use scope within oncology, rare diseases, neurology, and regenerative medicine. Key growth influencers in this market include technological advancements in cell processing, an increasing number of clinical trial projects, and favorable regulatory frameworks that expedite product approval processes. However, potential opportunities remain within the enhancement of scalable manufacturing processes and automation technologies. To capitalize on these opportunities, investment in facilitating partnerships with biotech firms focusing on nanoscale solutions and digital infrastructure for production analytics could be vital. Nonetheless, market growth is challenged by high manufacturing costs, stringent regulatory requirements, and a shortage of skilled workforce which may impact timely production and delivery of therapies. Moreover, limitations such as supply chain complexities and the nascent stage of many ATMP technologies create further obstacles. The best avenues for innovation and research could be in enhancing bioreactor technologies, improving gene editing tools, and optimizing cold chain logistics to support the stability and distribution of ATMPs. Emphasizing collaborations with academic institutions and biotech innovators may also drive technological breakthroughs. The market is dynamic, with high growth potential rooted in both therapeutic advancements and technological augmentations, but necessitates strategic navigation through regulatory and logistical challenges to sustain competitive leverage and maximize market share.

KEY MARKET STATISTICS
Base Year [2023] USD 7.54 billion
Estimated Year [2024] USD 8.74 billion
Forecast Year [2030] USD 22.74 billion
CAGR (%) 17.06%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Advanced Therapy Medicinal Products CDMO Market

The Advanced Therapy Medicinal Products CDMO Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Proliferation in prevalence of rare diseases with growing emergence of novel infectious diseases
    • Rising numbers of clinical trials for development of advanced therapy medicinal products
    • Increasing investments in pharmaceutical research and development worldwide
  • Market Restraints
    • High cost associated with outsourcing ATMP solutions
  • Market Opportunities
    • Adoption of advanced technologies by advanced therapy medicinal products CDMOs
    • Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
  • Market Challenges
    • Stringent governmental rules and regulations for ATMP approvals and commercialization

Porter's Five Forces: A Strategic Tool for Navigating the Advanced Therapy Medicinal Products CDMO Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Advanced Therapy Medicinal Products CDMO Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Advanced Therapy Medicinal Products CDMO Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Advanced Therapy Medicinal Products CDMO Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Advanced Therapy Medicinal Products CDMO Market

A detailed market share analysis in the Advanced Therapy Medicinal Products CDMO Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Advanced Therapy Medicinal Products CDMO Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Advanced Therapy Medicinal Products CDMO Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Advanced Therapy Medicinal Products CDMO Market

A strategic analysis of the Advanced Therapy Medicinal Products CDMO Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Advanced Therapy Medicinal Products CDMO Market, highlighting leading vendors and their innovative profiles. These include Abzena, Advanced Therapies, Inc. by WuXi AppTec, AGC Inc., Aldevron, Almac Group, Arranta Bio Holdings, LLC, Bio Elpida, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Inc., Coriolis Pharma Research GmbH, Eurofins Scientific SE, FUJIFILM Corporation, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, and VIVEBIOTECH S.L..

Market Segmentation & Coverage

This research report categorizes the Advanced Therapy Medicinal Products CDMO Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products, market is studied across Cell Therapy, Gene Therapy, and Tissue Engineered.
  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Indication, market is studied across Cardiology, Central Nervous System, Dermatology, Endocrine, Metabolic, Genetic, Gastroenterology, Hematology, Immunology & Inflammation, Infectious Disease, Musculoskeletal, Oncology, and Ophthalmology.
  • Based on End-Users, market is studied across Academic and Research Institutions, Biotechnology & Pharmaceutical Companies, Clinical Research Organizations (CROs), and Hospitals and Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Proliferation in prevalence of rare diseases with growing emergence of novel

infectious diseases

      • 5.1.1.2. Rising numbers of clinical trials for development of advanced therapy medicinal products
      • 5.1.1.3. Increasing investments in pharmaceutical research and development worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with outsourcing ATMP solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Adoption of advanced technologies by advanced therapy medicinal

products CDMOs

      • 5.1.3.2. Strategic alliance and expansion activities for R&D of advanced therapy medicinal products
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent governmental rules and regulations for ATMP approvals and

commercialization

  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Advanced Therapy Medicinal Products CDMO Market, by Products

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Gene Therapy
  • 6.4. Tissue Engineered

7. Advanced Therapy Medicinal Products CDMO Market, by Phase

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV

8. Advanced Therapy Medicinal Products CDMO Market, by Indication

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Central Nervous System
  • 8.4. Dermatology
  • 8.5. Endocrine, Metabolic, Genetic
  • 8.6. Gastroenterology
  • 8.7. Hematology
  • 8.8. Immunology & Inflammation
  • 8.9. Infectious Disease
  • 8.10. Musculoskeletal
  • 8.11. Oncology
  • 8.12. Ophthalmology

9. Advanced Therapy Medicinal Products CDMO Market, by End-Users

  • 9.1. Introduction
  • 9.2. Academic and Research Institutions
  • 9.3. Biotechnology & Pharmaceutical Companies
  • 9.4. Clinical Research Organizations (CROs)
  • 9.5. Hospitals and Clinics

10. Americas Advanced Therapy Medicinal Products CDMO Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Advanced Therapy Medicinal Products CDMO Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abzena
  • 2. Advanced Therapies, Inc. by WuXi AppTec
  • 3. AGC Inc.
  • 4. Aldevron
  • 5. Almac Group
  • 6. Arranta Bio Holdings, LLC
  • 7. Bio Elpida
  • 8. BlueReg
  • 9. Catalent Inc.
  • 10. CELONIC Group
  • 11. CGT Catapult
  • 12. Charles River Laboratories International, Inc.
  • 13. Coriolis Pharma Research GmbH
  • 14. Eurofins Scientific SE
  • 15. FUJIFILM Corporation
  • 16. Lonza Group
  • 17. Minaris Regenerative Medicine
  • 18. Oxford Biomedica PLC
  • 19. Patheon by Thermo Fisher Scientific Inc.
  • 20. Rentschler Biopharma SE
  • 21. REPROCELL Inc.
  • 22. RoslinCT
  • 23. Samsung Biologics
  • 24. VIVEBIOTECH S.L.

LIST OF FIGURES

  • FIGURE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET RESEARCH PROCESS
  • FIGURE 2. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET DYNAMICS
  • TABLE 7. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY TISSUE ENGINEERED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ENDOCRINE, METABOLIC, GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY IMMUNOLOGY & INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 201. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. ADVANCED THERAPY MEDICINAL PRODUCTS CDMO MARKET, FPNV POSITIONING MATRIX, 2023